<DOC>
	<DOCNO>NCT01548690</DOCNO>
	<brief_summary>This Phase 2a clinical study design provide data OCR-002 patient acute liver failure/acute liver injury ( ALF/ALI ) regard : - safety tolerability ; - metabolism compound glutamine phenylacetylglutamine ( PAGN ) ; - effect circulate ammonia level neurological function patient without impaired renal function continuous infusion different infusion rate . Subjects receive 120 hour ( 5 day ) drug infusion , follow 30 day follow-up visit post infusion . It anticipate early safety tolerability study , appropriate PK/PD data , lead development program use OCR-002 treatment hyperammonemia either due ALF possibly liver condition . The hypothesis : - Treatment OCR-002 safe tolerable patient acute liver failure/acute liver injury due acetaminophen overdose drug-induced liver injury , autoimmune hepatitis , viral hepatitis indeterminate etiology . - A dose 10-20g/24h ( 0.42-.83g/h ) achieve steady state plasma concentration within 6-12h little additional accumulation ALI/ALF setting . - Treatment OCR-002 reduce ammonia improve neurological function patient acute liver failure/severe acute liver injury .</brief_summary>
	<brief_title>Safety Study Ornithine Phenylacetate Treat Patients With Acute Liver Failure</brief_title>
	<detailed_description>There strong experimental clinical rationale use ammonia-lowering therapy ALF . Ammonia normally produce gut transform liver urea . As liver fails , ammonia increase systemic circulation enters brain . The result rapid rise ammonia relate compound cerebral circulation hepatic encephalopathy ( HE ) , reversible neuropsychiatric condition range severity mild impairment attention , delirium , development cerebral edema , coma death . This Phase 2a , multi-center , open-label study , conduct two cohort patient diagnose acute liver failure/acute liver injury ( ALF/ALI ) meet inclusion/exclusion criterion . This study design provide data OCR-002 regard - effect circulate ammonia level patient acute liver failure without impaired renal function different dos single continuous infusion - safety dose tolerability well - provide data metabolite , glutamine phenylacetylglutamine patient population . It anticipate early efficacy , safety , tolerability , Pharmacokinetic/Pharmacodynamic ( PK/PD ) dose-ranging study lead Phase 3 development program use OCR-002 treatment hyperammonemia due ALF . No clinical outcome measure formally study small sample size .</detailed_description>
	<mesh_term>Liver Failure</mesh_term>
	<mesh_term>Liver Failure , Acute</mesh_term>
	<mesh_term>Phenylacetic acid</mesh_term>
	<criteria>1 . Men woman , age 1865 ( reach 66th birthday ) . 2 . Acute liver failure , define development coagulopathy ( International normalize ratio [ INR ] ≥1.5 ) encephalopathy patient prior history liver disease , onset symptom within 28 day incite event . Patients may either history acetaminophen overdose ( define &gt; 4 g/day within 7 day presentation ) and/or detectable acetaminophen level serum , pattern liver function test typical acetaminophen toxicity ( bilirubin &lt; 10 mg/dL alanine aminotransferase ( ALT ) ≥1000 IU/L ) , diagnosis hepatitis A , hepatitis B , druginduced liver injury , autoimmune hepatitis indeterminate cause base standard criterion . 3 . ALI patient may also enrol ( meet criterion plus coagulopathy ( INR ≥ 2.0 ) evidence encephalopathy ) 4 . Written informed consent patient ( ALI ) patient 's legally authorize representative family member he/she consider encephalopathic ( ALF ) . 5 . Ammonia level ≥60 μmol/L baseline ( within 8h prior T0/initiation infusion ) . 6 . Serum creatinine level follow : 1 . Cohort 1 : Creatinine ≤1.5 mg/dL ; 2 . Cohort 2 : Creatinine &gt; 1.5 mg/dL &lt; 10mg/dL . 7 . Mean arterial pressure &gt; 65 mmHg . 1 . History chronic liver disease . 2 . Signs overt cerebral herniation , uncontrolled intracranial hypertension ICP monitoring ( applicable ) . 3 . Evidence Wilson 's disease , alcoholic hepatitis , biliary obstruction , ischemic hepatitis , severe acute renal tubular necrosis ( ATN ) due shock , patient ongoing hypotension . 4 . Significant gastrointestinal bleeding ( coffee ground per nasogastric tube and/or melena ) . 5 . Hemodynamic instability , define mean arterial pressure &lt; 65 mmHg . 6 . Cardiopulmonary complication pulmonary edema , aspiration pneumonia , heart failure . 7 . QT interval &gt; 500msec baseline EKG . 8 . Pregnancy . 9 . History malignancy cure cancer remission le 1 within past 5 year . Nonmelanoma skin cancer preclude participation trial . 10 . Concomitant administration drug know interfere renal excretion phenylacetylglutamine medication may induce hyperammonemia haloperidol , valproic acid systemic corticosteroid ( prohibit study ) . Alternative ammonia modify agent lactulose rifaximin consider standard care prohibit study period . 11 . Any health condition would preclude participation study judgment principal investigator .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>ornithine</keyword>
	<keyword>phenylacetate</keyword>
	<keyword>acetaminophen toxicity</keyword>
	<keyword>acute liver failure</keyword>
	<keyword>hepatitis B</keyword>
	<keyword>autoimmune hepatitis</keyword>
	<keyword>drug-induced liver injury</keyword>
</DOC>